Drug-resistant bacterial infections in hospitals, ICUs and combat settings demand new antibiotics and alternatives, but developers struggle commercially even when drugs succeed clinically. This report maps the pipeline of systemic antibacterials and bacteriophage therapeutics against priority resistant pathogens, from novel antibiotic classes and beta-lactamase inhibitors to phages, lysins and immunotherapies.
Three pages from this report, open in full. The rest opens when you own it.
Eight parts, the same tabs you get when you own the report.
7 use cases
The technology recommended for each, with the alternatives.
+ 4 more
12 classes
Every class compared, with its patent trend and leading players.
+ 9 more
6 sectors
Published November 2026 · © 2026 Berkeley FIT LLC. All rights reserved.
Mapped against the classes, with who sits in each.
+ 3 more
145 companies
Searchable and filterable by sector, class and relevance.
+ 142 more
547 products
The products behind the companies, grouped by class.
+ 544 more
2,282 patents
Dominant and emerging holders for each mechanism of action.
+ 7 more
4 pathways
What each means for timelines and cost.
2 catalogs
Take the data with you.